Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin
M LeBel - Canadian Journal of Infectious Diseases and Medical …, 1993 - hindawi.com
M LeBel
Canadian Journal of Infectious Diseases and Medical Microbiology, 1993•hindawi.comObjective: To compare the pharmacokinetic properties of two new macrolide antibiotics,
clarithromycin and azithromycin, with those of the prototype macrolide, erythromycin. Data
Sources: Primarily peer review journals were searched for papers describing the
pharmacokinetics of these new macrolides. Study Selection: Fifteen in vitro and clinical
studies of clarithromycin and azithromycin and one clinical abstract on clarithromycin from
the past four years were selected for review. Data Extraction: Data relevant to the …
clarithromycin and azithromycin, with those of the prototype macrolide, erythromycin. Data
Sources: Primarily peer review journals were searched for papers describing the
pharmacokinetics of these new macrolides. Study Selection: Fifteen in vitro and clinical
studies of clarithromycin and azithromycin and one clinical abstract on clarithromycin from
the past four years were selected for review. Data Extraction: Data relevant to the …
Objective
To compare the pharmacokinetic properties of two new macrolide antibiotics, clarithromycin and azithromycin, with those of the prototype macrolide, erythromycin.
Data Sources
Primarily peer review journals were searched for papers describing the pharmacokinetics of these new macrolides.
Study Selection
Fifteen in vitro and clinical studies of clarithromycin and azithromycin and one clinical abstract on clarithromycin from the past four years were selected for review.
Data Extraction
Data relevant to the pharmacokinetic characteristics of clarithromycin, azithromycin and, to a lesser extent, erythromycin were selected for presentation in this comparison.
Data Synthesis
By reviewing the available studies, it was possible to construct pharmacokinetic profiles of the new compounds, and to compare them with each other and with erythromycin.
Conclusions
Both clarithromycin and azithromycin have been shown to have an antibacterial spectrum and pharmacokinetic profile superior to that of erythromycin. The differences between the new compounds, however, may not be that significant. Each is likely to become a first-line therapeutic option in specific instances, which will become better delineated as clinical research on these new macrolides continues.
hindawi.com